α-synuclein stabilizes the proteasome activator Blm10/PA200, which assembles a proteasome variant capable of degrading both monomeric and oligomeric α-synuclein while resisting proteotoxic inhibition. This identifies a cellular mechanism that restores protein degradation capacity under the proteotoxic stress characteristic of Parkinson's disease.
Key Points
- Blm10/PA200-capped proteasomes degrade α-synuclein monomers and oligomers efficiently
- These proteasomes resist α-synuclein-induced inhibition unlike standard proteasome variants
- α-synuclein phosphorylation at S129 stabilizes Blm10 through autophagy inhibition
Longevity Analysis
Protein accumulation and degradation failure define the trajectory of neurodegeneration. This work reveals that cells possess an adaptive response—activating a specialized proteasome configuration when confronted with α-synuclein stress. The capacity to maintain protein clearance under toxicity, rather than succumbing to it, represents a critical distinction between aging that preserves function and aging that permits disease. Understanding how to sustain or restore this proteolytic resilience addresses one of the fundamental reasons neurodegenerative disease takes hold.
Original published by Wiley Aging Cell, by Tariq T. Ali, Anton Zhornyak, Madiha Merghani, Zora Buschenlange, Eri Sakata, Tiago F. Outeiro, Blagovesta Popova, Gerhard H. Braus .